24/7 Market News Snapshot 29 October, 2024 – Eledon Pharmaceuticals, Inc. Common Stock (NASDAQ:ELDN)

October 29, 2024

DENVER, Colo., 29 October, 2024 (247marketnews.com) – (NASDAQ:ELDN) are discussed in this article.
Eledon Pharmaceuticals, Inc. has recently experienced a significant upswing in its stock price, with shares increasing over 25% in pre-market trading, now valued at approximately $4.224. This surge comes amid heightened investor interest and robust trading activity, with 787.80K shares exchanged. The positive momentum reflects growing optimism within the biotechnology sector, positioning Eledon for potential future advancements.

Further bolstering this optimism, Eledon has announced promising results from a recent clinical trial involving its investigational drug, tegoprubart, an anti-CD40L antibody. In this trial, two out of three islet transplant recipients who participated in an immunosuppression regimen containing tegoprubart achieved insulin independence—an important milestone in the management of type 1 diabetes. These participants maintained normal glucose control, evidenced by hemoglobin A1c levels within expected ranges, while the third individual is progressing positively toward the same goal following their transplant.

The study indicated that islet engraftment rates in patients treated with tegoprubart were estimated to be three to five times higher than those receiving standard tacrolimus-based therapies. Importantly, the treatment was well tolerated without unexpected adverse events reported, showcasing the safety of the drug.

These findings will be shared in an oral session at the upcoming 5th IPITA/HSCI/Breakthrough T1D Stem Cells Summit, reinforcing Eledon’s position as a leader in innovative immunosuppressive strategies for transplantation. Eledon’s CEO, David-Alexandre C. Gros, M.D., emphasized the significance of these results in advancing the development of new therapies aimed at improving the lives of individuals affected by type 1 diabetes, underscoring the company’s dedication to achieving breakthroughs in the field.

Related news for (ELDN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.